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ABSTRACT _
Until 1994, rates of noncompliance for lipid-lowering
therapies were largely drawn from clinical trials and
showed favorable risks for drug discontinuation, rang-
ing from 4-15% for I-year risk to 11-30% for 5-year
risk. Although cross-study comparisons are difficult to
make because of variations in study design and mea-
sures collected, when evaluating compliance to antihy-
Compliance with prescribed drug therapy is an is-sue of widespread concern. Do patients adhere
to suggested treatment regimens? Lack of compli-
ance with drug therapy encompasses the improper
use of a prescription to complete discontinuation
of the drug. Estimates of compliance with lipid-
lowering therapy have largely been drawn from
randomized clinical trials, which have reported the
1-year risk of discontinuation to be between 4%
and 15% [1-4]. Of the longer trials, the 5-year risk
was reported to be between 11% and 30% [1-4].
These rates suggest that a large proportion of pa-
tients are able to stay compliant with therapy for
extended periods of time. However, clinical trials
usually evaluate patient compliance within the con-
fines of a monitored study. What happens in the
real world? Prior to 1994, little information existed
about compliance with lipid-lowering therapy in
primary care settings. Published reports of compli-
ance [5,6] did not accurately account for variable
times of patient follow-up, and so did not reflect
the actual risk of noncompliance. As a result, the
reported rates of discontinuation could not be val-
idly compared to rates acquired in clinical trials. It
was of interest, then, to investigate, over a specific
time frame, the compliance with lipid-lowering
therapy of patients from primary care settings and
compare these results to those found in clinical tri-
als. Portions of this review have been reported in an
article that appeared in the New England Journal
ofMedicine [7].
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perlipidemic drugs in primary care settings, results in
general show substantially higher rates of discontinua-
tion than those reported from randomized clinical tri-
als. Recent studies from the United States, Australia, and
Canada support the conclusion that adherence to lipid-
lowering drugs is very poor in primary care settings.
A Study of Noncompliance in Primary
Healthcare Settings
With the aim of determining antihyperlipidemic
drug discontinuation rates in primary care set-
tings, and to compare these rates to those in ran-
domized clinical trials, two health maintenance
organizations (HMOs) were studied using a retro-
spective cohort design [7]. The Fallon Community
Health Plan and the Harvard Community Health
Plan provided demographic, enrollment, and health
services data for patients with a documented lipid
disorder who began drug therapy from 1988 to
1990. The patient population was 52 % female,
with a mean age of 57 years (range 12-88 years).
Approximately 53% of patients had a diagnosis of
hypertension and 12% had a diagnosis of diabetes
in the automated health plan records.
Identification of drug discontinuations was per-
formed using computerized databases and chart
review. Comparisons were limited to niacin, lova-
statin, gemfibrozil, and the bile acid sequestrants,
cholestyramine and colestipol. The study popula-
tion consisted of 2369 new users of lipid-lowering
drugs during the study period, accounting for
3223 prescribed courses of drug therapy. The bile
acid sequestrants were the most commonly dis-
pensed agents (41.4%), followed by niacin (22.6%),
lovastatin (16.7%) and gemfibrozil (14.1 %).
There were 1047 discontinuations, accounting
for 32% of the prescribed courses of therapy. Of
all discontinuations, the majority resulted from
switching to a new agent (56%), but 30% of pa-
tients received no other drug therapy during the
study period. Eleven percent had their treatment
supplemented with additional agents and 3% con-
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tinued on a single agent of an initial combination
therapy. Using survival analysis techniques, the
I-year risk of discontinuation for all the drug ther-
apies combined was 38%. Table 1 lists the 'l-year
risk of discontinuation for the four most com-
monly prescribed individual classes of agents. The
lowest discontinuation rate measured was for lova-
statin at 15%, followed by gemfibrozil at 37%,
bile acid sequestrants at 41 %, and niacin at 46%.
On the whole, adverse events accounted for ap-
proximately 60% of discontinuations, and drug
ineffectiveness accounted for 30%.
Comparison to Randomized Clinical Trials
Randomized clinical trials of at least 6 months'
duration and published from 1975 to 1993 were
identified from searching the medical literature.
Of the 17 long-term clinical trials that met study cri-
teria, duration of follow-up ranged from 6 months
to over 7 years (see [7] for individual study cita-
tions). Comparing summary estimations of the
l-year risk of discontinuation, bile acid sequestrants,
niacin, and gemfibrozil all demonstrated risks sub-
stantially lower than those reported in the HMOs
(Table I). Bile acid sequestrants showed a 'l-year
risk of discontinuation of 31 % in clinical trials
compared to 41 % in the HMOs; gemfibrozil
showed a risk of 15% in clinical trials compared
to the 37% found in HMOs; and niacin showed a
discontinuation risk of 4% in clinical trials com-
pared to 46% in HMOs. Clinical trials providing
longer periods of study showed a widened gap be-
tween the risks from HMOs and clinical trials.
Unlike the other antihyperlipidemic agents, lova-
statin was demonstrated to have similar rates of
noncompliance in the clinical trials and HMOs
(16% vs. 15%).
Recent Reports of Compliance
Two primary care studies in the United States that
included discontinuation (but not specific risks be-
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cause they did not incorporate variations of pa-
tient follow-up time) reported frequencies of dis-
continuation ranging from 4% with lovastatin to
65% with bile acid sequestrants [8], and 52%
with lovastatin to 73% with niacin [9]. In a recent
Australian study [l0], the overall I-year risk of
discontinuation was 60% and the specific risk for
gemfibrozil was 78 %, both of which were much
higher than that reported in the study by Andrade
et al. [7] (see Table 1). The main reason for dis-
continuation in the Australian study was that the
patients were unconvinced that there was a need
for treatment, whereas in the primary care study
using HMOs, discontinuation was mainly due to
adverse drug effects. In the Australian study [10],
Simons et al. also reported a I-year risk of discon-
tinuation for two other agents, pravastatin and
simvastatin, of 56% and 57%, respectively. A pri-
mary care study in Saskatchewan [11], using the
Saskatchewan Drug Prescription Plan, reported
the percentage of patients who stopped taking the
drug after one prescription. The lowest estimate
was for simvastatin, for which 24% of patients
never renewed their prescriptions, followed closely
by pravastatin, lovastatin, gemfibrozil, and choles-
tyramine at 25%, 26%, 35%, and 53%, respec-
tively. Niacin, at 69% of patients discontinuing
use after one prescription, was the highest.
On the other hand, recent large-scale random-
ized clinical trials have still reported favorable
rates of discontinuation. One-year risks of 16%
and 5-year risks of 2-30% have been published
[12-14]. This is likely due to the selection criteria
used and, more importantly, to these patients be-
ing followed up and observed much more closely
than the average patient in a primary care setting.
Little information exists for compliance to diet
therapy. In the Cholesterol Reduction Intervention
Study [15], diet therapy also had poor compli-
ance. At the start of the study, 50% of patients re-
ceiving step-care therapy, beginning with either ni-
acin or bile acid sequestrants, were not compliant
with their diet therapy and 40% of lovastatin us-
ers were not compliant.
Table lOne-year risk of antihyperlipidemic drug
discontinuation
*Data from two health maintenance organizations [7].
'See [7] for study citations.
'Values in parentheses are 95% confidence intervals. as percentages.
Drug
Lovastatin
Gemfibrozil
Bile acid sequestrants
Niacin
Primary care~
15%(11-19)
37% (31-43)
41% (38-44)
46% (42-51)
Clinical trials"
16% (15-17)
15% (13-16)
31% (30-33)
4% (3-5)
Conclusions
The general conclusion of the compliance studies
is that adherence to lipid-lowering drugs is very
poor in primary care settings. The importance to
policy-makers assessing cost-effectiveness is that
the reports found in randomized clinical trials do
not accurately reflect the compliance with lipid-
lowering therapy in the real world. Cautious inter-
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pretation is necessary because discontinuation rates
may not accurately reflect the success rate that
lipid-lowering therapeutic agents have in primary
care settings. Biases were likely present in the pre-
scribing patterns of the agents at these two man-
aged care plans, which make direct head-to-head
comparisons of the agents inappropriate, based on
these data alone.
Editor·s Addendum
A recent article [16] was published after the
ISPOR Lipid Conference and therefore was not
discussed in the conference presentation. It de-
scribes a cross-national study that examined the
persistence of use of lipid-lowering agents in eld-
erly patients who received Medicaid, state phar-
macy assistance programs, or Quebec's provincial
medical care program between the period of 1990
to 1991. The study showed high rates of discon-
tinuation of about 40% in 1 year and 48% in 5
years. In contrast to Andrade's findings on compli-
ance in managed care populations [7], statins were
the most frequently prescribed agent (39.4%) in
this low-income or indigent elderly population.
Persistency rates for starins were significantly
higher than that of other agents. Patients with co-
morbid conditions such as hypertension, diabetes,
or coronary artery disease had significantly higher
rates of compliance. This study supports the need
to consider compliance in the real world in cost-
effectiveness analyses of lipid-lowering agents. In
addition, variation in rates of compliance, depen-
dent upon the choice of agent prescribed, cornor-
bidity, and socioeconomic status of the patient
population, should be considered.
This article was prepared with the assistance of BioMed-
Com Consultants inc., Montreal, Canada.
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